Send to

Choose Destination
ACS Med Chem Lett. 2016 Jul 20;7(9):847-51. doi: 10.1021/acsmedchemlett.6b00215. eCollection 2016 Sep 8.

Cellular Activity of New Small Molecule Protein Arginine Deiminase 3 (PAD3) Inhibitors.

Author information

Department of Chemistry, Yale University , New Haven, Connecticut 06520, United States.


The protein arginine deiminases (PADs) catalyze the post-translational deimination of arginine side chains. Multiple PAD isozymes have been characterized, and abnormal PAD activity has been associated with several human disease states. PAD3 has been characterized as a modulator of cell growth via apoptosis inducing factor and has been implicated in the neurodegenerative response to spinal cord injury. Here, we describe the design, synthesis, and evaluation of conformationally constrained versions of the potent and selective PAD3 inhibitor 2. The cell activity of representative inhibitors in this series was also demonstrated for the first time by rescue of thapsigargin-induced cell death in PAD3-expressing HEK293T cells.


Protein arginine deiminases; apoptosis inducing factor; small molecule inhibitor; spinal cord injury

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center